Shijiazhuang

Researchers are evaluating the real-world effectiveness of mavacamten treatment in Chinese adults who have symptomatic obstructive hypertrophic cardiomyopathy HCM. The study aims to assess how mavacamten works for patients with this heart condition based on current clinical practice, following guidelines from leading heart associations. It focuses on adults aged 18 and older who have documented obstructive HCM and symptoms classified as New York Heart Association NYHA class II or III. Participants included are those who have started or are scheduled to start mavacamten treatment according to clinical needs. The treatment is given as directed by the product label. The study observes changes in heart function, specifically the left ventricular outflow tract LVOT gradient, and tracks participants for up to 96 weeks. Follow-up assessments occur at various points including weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96 to monitor symptoms and heart performance. During the study, participants heart function is assessed using echocardiography and symptom classification by NYHA class. Researchers collect detailed clinical data such as heart structure and function measurements, medication doses, and LVOT gradients throughout the follow-up period. The main outcomes measured are changes in LVOT gradients at weeks 48 and 96, along with symptom improvements. This observational study involves no placebo or comparison group and records how patients respond to mavacamten in routine care over nearly two years.